Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Previous Page

Next Page

Page Background

All ALK TKIs work better into the brain with previous RT

Previous RT

No Previous RT

PFS

icRR

Gadgeel – Ann Oncol 2018